Observational Study of Vectibix With Chemotherapy for Metastatic Colorectal Cancer Patients

Inclusion Criteria * Subject is ≥ 18 years of age at date of enrolment * Histologically or cytologically confirmed carcinoma of colon or rectum * Subject with metastatic carcinoma of colon or rectum * Confirmed wild-type RAS status of tumour * Subjects whose care will be managed primarily by the enrolling physician and/ or all records will be available * Tumour assessment (ie, computed tomography \[CT\]/magnetic resonance imaging \[MRI\]) within 12 weeks (84 days) prior to first Vectibix® infusion. * Subjects treated with at least one infusion of Vectibix® in combination with chemotherapy a maximum of 84 days before entering study: first-line in combination with FOLFOX (folinic acid, leucovorin, fluorouracil \[5FU\], oxaliplatin) or second-line in combination with FOLFIRI (folinic acid, leucovorin, 5FU, irinotecan) in subjects who have received first-line fluoropyrimidine-based chemotherapy (excluding irinotecan) for treatment of wild-type RAS mCRC per approved prescribing information * Subject or subject's legally acceptable representative has provided informed consent (for countries where required per local regulations) * Subjects treated with Vectibix® in accordance with the current version of the Summary of Product Characteristics (SmPC) Exclusion Criteria * Ongoing or planned concurrent participation in any clinical study involving Investigational Product that has not been approved by the European Medicines Agency for any indication * Ongoing or planned concurrent participation in any clinical study where the dosing of Vectibix® is determined by the protocol (participation in clinical trials on an approved drug and observational trials are permitted but these cannot mandate how mCRC should be treated)